In our recent study, we found that 10% of colon cancer patients had HER2 amplification and HER2-targeting agents demonstrate anti-tumor efficacy in HER2-amplified colon cancer cell lines.20 Recently, HER2 V842l mutation in breast cancer was shown to be activating mutations associated with drug sensitive to neratinib.21 We plan to test the anti-tumor efficacy of neratinib in this HER2 mutated colon cancer PDX model. This evidence concerns the gene ERBB2 and neoplasm.